Efficacy and association analysis of high‑dose methotrexate in the treatment of children with acute lymphoblastic leukemia

Gong,Fangwei; Meng,Qingjun; Liu,Chengjuan; Zhao,Yeqi

doi:10.3892/ol.2019.10128

Efficacy and association analysis of high‑dose methotrexate in the treatment of children with acute lymphoblastic leukemia

Authors:
- Fangwei Gong
- Qingjun Meng
- Chengjuan Liu
- Yeqi Zhao
View Affiliations

Affiliations: Ward 2, Department of Pediatrics, The People's Hospital of Pingyi County, Linyi, Shandong 273300, P.R. China, Ward 6, Department of Pediatrics, The People's Hospital of Pingyi County, Linyi, Shandong 273300, P.R. China
Published online on: March 8, 2019 https://doi.org/10.3892/ol.2019.10128
Pages: 4423-4428

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Effect of high‑dose methotrexate (MTX) on children with acute lymphoblastic leukemia (ALL) with different subtypes and disease courses was investigated. A retrospective analysis of 207 children with ALL who were admitted to the People's Hospital of Pingyi County from March 2014 to June 2017 was carried out. According to the subtype of the disease, the children were divided into two groups. B‑lineage group: ALL occurred in B‑lineage lymphocytes (n=128); T‑lineage group: ALL occurred in T‑lineage lymphocytes (n=79). According to the disease course, the children were divided into three groups. High‑risk group: disease course >15 days (n=67); moderate‑risk group: disease course >8 and <15 days (n=58); low‑risk group: disease course <8 days (n=82). The plasma concentration, calcium formyltetrahydrofolate (CF) rescue times and adverse reactions were compared at 12 h (T1), 48 h (T2), and 72 h (T3) after MTX infusion. The plasma concentration in B‑lineage group was significantly higher than that in the T‑lineage group at T2 and T3 (P<0.05). The incidence of adverse reactions in children with ALL in the B‑lineage group was significantly higher than that in the T‑lineage group (P<0.05). The CF rescue times in high‑risk group were more than that in moderate‑ and low‑risk groups (P<0.05). The incidence of adverse reactions in the high‑risk group was significantly higher than that in the moderate‑ and low‑risk groups (P<0.05), and in the moderate‑risk group was significantly higher than that in the low‑risk group (P<0.05). Compared with T‑lineage ALL children, high‑dose MTX causes more toxic injury to B‑lineage ALL children. During clinical application of MTX in the treatment of ALL, close attention should be paid to the changes of the vital signs of patients, and timely CF rescue should be performed.

View Figures

View References

1	Wang W, Zimmerman G, Huang X, Yu S, Myers J, Wang Y, Moreton S, Nthale J, Awadallah A, Beck R, et al: Aberrant Notch signaling in the bone marrow microenvironment of acute lymphoid leukemia suppresses osteoblast-mediated support of hematopoietic niche function. Cancer Res. 76:1641–1652. 2016. View Article : Google Scholar : PubMed/NCBI
2	Nicolato A, Nouér SA, Garnica M, Portugal R, Maiolino A and Nucci M: Invasive fungal diseases in patients with acute lymphoid leukemia. Leuk Lymphoma. 57:2084–2089. 2016. View Article : Google Scholar : PubMed/NCBI
3	El-Jawahri A, Li S, Ballen KK, Cutler C, Dey BR, Driscoll J, Hunnewell C, Ho VT, McAfee SL, Poliquin C, et al: Phase II trial of reduced-intensity busulfan/clofarabine conditioning with allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoid leukemia. Biol Blood Marrow Transplant. 22:80–85. 2016. View Article : Google Scholar : PubMed/NCBI
4	Duque-Afonso J, Lin CH, Han K, Wei MC, Feng J, Kurzer JH, Schneidawind C, Wong SH, Bassik MC and Cleary ML: E2A-PBX1 remodels oncogenic signaling networks in B-cell precursor acute lymphoid leukemia. Cancer Res. 76:6937–6949. 2016. View Article : Google Scholar : PubMed/NCBI
5	Fitzgerald JC, Weiss SL, Maude SL, Barrett DM, Lacey SF, Melenhorst JJ, Shaw P, Berg RA, June CH, Porter DL, et al: Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit Care Med. 45:e124–e131. 2017. View Article : Google Scholar : PubMed/NCBI
6	Jacoby E, Nguyen SM, Fountaine TJ, Welp K, Gryder B, Qin H, Yang Y, Chien CD, Seif AE, Lei H, et al: CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. Nat Commun. 7:123202016. View Article : Google Scholar : PubMed/NCBI
7	Frey NV and Porter DL: Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. Hematology (Am Soc Hematol Educ Program). 2016:567–572. 2016. View Article : Google Scholar : PubMed/NCBI
8	Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, et al International Extranodal Lymphoma Study Group (IELSG), : Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: Results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 3:e217–e227. 2016. View Article : Google Scholar : PubMed/NCBI
9	Larsen EC, Devidas M, Chen S, Salzer WL, Raetz EA, Loh ML, Mattano LA Jr, Cole C, Eicher A, Haugan M, et al: Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: A report from Children's Oncology Group Study AALL0232. J Clin Oncol. 34:2380–2388. 2016. View Article : Google Scholar : PubMed/NCBI
10	Schmiegelow K, Attarbaschi A, Barzilai S, Escherich G, Frandsen TL, Halsey C, Hough R, Jeha S, Kato M, Liang DC, et al Ponte di Legno toxicity working group, : Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: A Delphi consensus. Lancet Oncol. 17:e231–e239. 2016. View Article : Google Scholar : PubMed/NCBI
11	Krull KR, Cheung YT, Liu W, Fellah S, Reddick WE, Brinkman TM, Kimberg C, Ogg R, Srivastava D, Pui CH, et al: Chemotherapy pharmacodynamics and neuroimaging and neurocognitive outcomes in long-term survivors of childhood acute lymphoblastic leukemia. J Clin Oncol. 34:2644–2653. 2016. View Article : Google Scholar : PubMed/NCBI
12	Asselin BL, Devidas M, Chen L, Franco VI, Pullen J, Borowitz MJ, Hutchison RE, Ravindranath Y, Armenian SH, Camitta BM, et al: Cardioprotection and safety of dexrazoxane in patients treated for newly diagnosed T-cell acute lymphoblastic leukemia or advanced-stage lymphoblastic non-Hodgkin lymphoma: A report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404. J Clin Oncol. 34:854–862. 2016. View Article : Google Scholar : PubMed/NCBI
13	Iparraguirre L, Gutierrez-Camino A, Umerez M, Martin-Guerrero I, Astigarraga I, Navajas A, Sastre A, Garcia de Andoin N and Garcia-Orad A: MiR-pharmacogenetics of methotrexate in childhood B-cell acute lymphoblastic leukemia. Pharmacogenet Genomics. 26:517–525. 2016. View Article : Google Scholar : PubMed/NCBI
14	Wojtuszkiewicz A, Raz S, Stark M, Assaraf YG, Jansen G, Peters GJ, Sonneveld E, Kaspers GJ and Cloos J: Folylpolyglutamate synthetase splicing alterations in acute lymphoblastic leukemia are provoked by methotrexate and other chemotherapeutics and mediate chemoresistance. Int J Cancer. 138:1645–1656. 2016. View Article : Google Scholar : PubMed/NCBI
15	Jabbour E and Kantarjian H: Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. Am J Hematol. 89:547–556. 2014. View Article : Google Scholar : PubMed/NCBI
16	Burnett AK, Russell NH, Hills RK, Hunter AE, Kjeldsen L, Yin J, Gibson BE, Wheatley K and Milligan D: Optimization of chemotherapy for younger patients with acute myeloid leukemia: Results of the medical research council AML15 trial. J Clin Oncol. 31:3360–3368. 2013. View Article : Google Scholar : PubMed/NCBI
17	Hough R, Rowntree C, Goulden N, Mitchell C, Moorman A, Wade R and Vora A: Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia: Results from UKALL 2003. Br J Haematol. 172:439–451. 2016. View Article : Google Scholar : PubMed/NCBI
18	Hoelzer D, Bassan R, Dombret H, Fielding A, Ribera JM and Buske C; ESMO Guidelines Committee, : Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 27 Suppl 5:v69–v82. 2016.PubMed/NCBI
19	Liang DC, Yang CP, Liu HC, Jaing TH, Chen SH, Hung IJ, Yeh TC, Lin TH, Lai CL, Lai CY, et al: NUDT15 gene polymorphism related to mercaptopurine intolerance in Taiwan Chinese children with acute lymphoblastic leukemia. Pharmacogenomics J. 16:536–539. 2016. View Article : Google Scholar : PubMed/NCBI
20	Al-Ghobashy MA, Hassan SA, Abdelaziz DH, Elhosseiny NM, Sabry NA, Attia AS and El-Sayed MH: Development and validation of LC-MS/MS assay for the simultaneous determination of methotrexate, 6-mercaptopurine and its active metabolite 6-thioguanine in plasma of children with acute lymphoblastic leukemia: Correlation with genetic polymorphism. J Chromatogr B Analyt Technol Biomed Life Sci. 1038:88–94. 2016. View Article : Google Scholar : PubMed/NCBI
21	Howard SC, McCormick J, Pui CH, Buddington RK and Harvey RD: Preventing and managing toxicities of high-dose Methotrexate. Oncologist. 21:1471–1482. 2016. View Article : Google Scholar : PubMed/NCBI
22	Carbonnel F, Colombel JF, Filippi J, Katsanos KH, Peyrin-Biroulet L, Allez M, Nachury M, Novacek G, Danese S, Abitbol V, et al: European Crohn's and Colitis Organisation; Groupe d'Étude Thérapeutique des Affections Inflammatoires Digestives: Methotrexate is not superior to placebo for inducing steroid-free remission, but induces steroid-free clinical remission in a larger proportion of patients with ulcerative colitis. Gastroenterology. 150:380–388.e4. 2016. View Article : Google Scholar : PubMed/NCBI
23	Yamanaka H, Tanaka Y, Takeuchi T, Sugiyama N, Yuasa H, Toyoizumi S, Morishima Y, Hirose T and Zwillich S: Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: An open-label, long-term extension study. Arthritis Res Ther. 18:342016. View Article : Google Scholar : PubMed/NCBI
24	Gitlin AD, von Boehmer L, Gazumyan A, Shulman Z, Oliveira TY and Nussenzweig MC: Independent roles of switching and hypermutation in the development and persistence of B lymphocyte memory. Immunity. 44:769–781. 2016. View Article : Google Scholar : PubMed/NCBI
25	Woessmann W, Seidemann K, Mann G, Zimmermann M, Burkhardt B, Oschlies I, Ludwig WD, Klingebiel T, Graf N, Gruhn B, et al BFM Group, : The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: A report of the BFM Group Study NHL-BFM95. Blood. 105:948–958. 2005. View Article : Google Scholar : PubMed/NCBI
26	Conter V, Valsecchi MG, Buldini B, Parasole R, Locatelli F, Colombini A, Rizzari C, Putti MC, Barisone E, Lo Nigro L, et al: Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: A retrospective analysis. Lancet Haematol. 3:e80–e86. 2016. View Article : Google Scholar : PubMed/NCBI